Animal models for metabolic, neuromuscular and ophthalmological rare diseases

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Nature reviews. Drug discovery

• Publication date

  2013-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrd3831PMID 23493083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amyotrophic lateral sclerosis.

  2012cited by this paper
• A call for transparent reporting to optimize the predictive value of preclinical research

  2012cited by this paper
• Animal models for Gaucher disease research

  2011cited by this paper
• European regulation on orphan medicinal products: 10 years of experience and future perspectives.

  2011cited by this paper
• Registries in chronic disease: coming your way soon? Registries--problems, solutions and the future.

  2011cited by this paper
• Overview of the mucopolysaccharidoses.

  2011cited by this paper
• Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.

  2011cited by this paper
• European regulation on orphan medicinal products: 10 years of experience and future perspectives

  2011cited by this paper
• Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.

  2011cited by this paper
• Guidelines for preclinical animal research in ALS/MND: A consensus meeting

  2010cited by this paper
• Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations.

  2010cited by this paper
• The development of the rat model of retinopathy of prematurity

  2010cited by this paper
• Review of the Ocular Angiogenesis Animal Models

  2009cited by this paper
• Autoimmune disorders of the neuromuscular junction.

  2009cited by this paper
• Does neuroinflammation fan the flame in neurodegenerative diseases?

  2009cited by this paper
• Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics

  2009cited by this paper
• Amyotrophic lateral sclerosis

  2009cited by this paper
• Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

  2009cited by this paper
• Cyclosporin A Eye Drops Inhibit Fibrosis and Inflammatory Cell Infiltration in Murine Type I Allergic Conjunctivitis without Affecting the Early-Phase Reaction

  2009cited by this paper
• Neural deficits contribute to respiratory insufficiency in Pompe disease

  2009cited by this paper
• Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis

  2009cited by this paper
• Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

  2009cited by this paper
• Ocular gene therapy: current progress and future prospects.

  2009cited by this paper
• Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring

  2009cited by this paper
• Large animal models of neurological disorders for gene therapy.

  2009cited by this paper
• Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.

  2009cited by this paper
• Generation of transgenic monkeys with human inherited genetic disease.

  2009cited by this paper
• Animal models and different therapies for treatment of retinitis pigmentosa.

  2009cited by this paper
• Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial

  2008cited by this paper
• Rpe65-/- and Lrat-/- mice: comparable models of leber congenital amaurosis.

  2008cited by this paper
• Temporal Neuropathologic and Behavioral Phenotype of 6neo/6neo Pompe Disease Mice

  2008cited by this paper
• ALS2/Alsin Knockout Mice and Motor Neuron Diseases

  2008cited by this paper
• Chemically modified β-glucuronidase crosses blood–brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII

  2008cited by this paper
• Mouse Models of Experimental Autoimmune Uveitis

  2008cited by this paper
• Rodent genetic models of Huntington disease.

  2008cited by this paper
• Autoimmune disorders of the neuromuscular junction.

  2008cited by this paper
• NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis.

  2008cited by this paper
• Relevance of Animal Models to Human Uveitis

  2008cited by this paper
• Effect of gene therapy on visual function in Leber's congenital amaurosis.

  2008cited by this paper
• Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer.

  2008cited by this paper
• Non-human primate models in allo-transplantation research: A short review

  2008cited by this paper
• Motor Neuron Disease Occurring in a Mutant Dynactin Mouse Model Is Characterized by Defects in Vesicular Trafficking

  2008cited by this paper
• Characterization of Naturally Occurring CD4+CD25+ Regulatory T Cells in Rhesus Monkeys

  2008cited by this paper
• Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels.

  2008cited by this paper
• SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model.

  2008cited by this paper
• Molecular and cellular basis of calpainopathy (limb girdle muscular dystrophy type 2A).

  2007cited by this paper
• AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not α-sarcoglycan deficiency

  2007cited by this paper
• Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

  2007cited by this paper
• Phenotypic Correction of α-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector.

  2007cited by this paper
• Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue.

  2007cited by this paper
• Autoimmune Uveitis Elicited with Antigen-Pulsed Dendritic Cells Has a Distinct Clinical Signature and Is Driven by Unique Effector Mechanisms: Initial Encounter with Autoantigen Defines Disease Phenotype1

  2007cited by this paper
• Enzyme Replacement Therapy for Murine Hypophosphatasia

  2007cited by this paper
• Lost in translation: Treatment trials in the SOD1 mouse and in human ALS

  2007cited by this paper
• Pompe disease: current state of treatment modalities and animal models.

  2007cited by this paper
• Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy.

  2007cited by this paper
• Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences

  2007cited by this paper
• Characterization of Huntingtin Pathologic Fragments in Human Huntington Disease, Transgenic Mice, and Cell Models

  2007cited by this paper
• Early alterations in the electrophysiological properties of rat spinal motoneurones following neonatal axotomy

  2007cited by this paper
• Phenotypic correction of alpha-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector.

  2007cited by this paper
• Pathology of Mucopolysaccharidosis IIIA in Huntaway Dogs

  2007cited by this paper
• Definition and diagnostic criteria

  2007cited by this paper
• Elovl4 5-bp-deletion knock-in mice develop progressive photoreceptor degeneration.

  2006cited by this paper
• Large animal models and gene therapy

  2006cited by this paper
• Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies

  2006cited by this paper
• Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat.

  2006cited by this paper
• Diagnosis of Fabry disease: the role of screening and case-finding studies -- Fabry Disease: Perspectives from 5 Years of FOS

  2006cited by this paper
• Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.

  2005cited by this paper
• Effective gene therapy for an inherited CNS disease in a large animal model

  2005cited by this paper
• Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA).

  2005cited by this paper
• Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors

  2005cited by this paper
• Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis.

  2005cited by this paper
• Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase.

  2005cited by this paper
• Knock-in mouse models of Huntington’s disease

  2005cited by this paper
• Importance of immunotoxicity in safety assessment: a medical toxicologist's perspective.

  2004cited by this paper
• Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.

  2004cited by this paper
• Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.

  2004cited by this paper
• AMPA receptor activation, but not the accumulation of endogenous extracellular glutamate, induces paralysis and motor neuron death in rat spinal cord in vivo

  2004cited by this paper
• Genetics of rare diseases of the kidney: learning from mouse models

  2004cited by this paper
• Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study.

  2004cited by this paper
• Force impairment in calpain 3–deficient mice is not correlated with mechanical disruption

  2003cited by this paper
• Experimental Autoimmune Uveoretinitis in the Rat and Mouse

  2003cited by this paper
• Biochemical Characterization of Porphobilinogen Deaminase-Deficient Mice During Phenobarbital Induction of Heme Synthesis and the Effect of Enzyme Replacement

  2003cited by this paper
• Patterned Purkinje cell degeneration in mouse models of Niemann‐Pick type C disease

  2003cited by this paper
• Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease.

  2003cited by this paper
• Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.

  2003cited by this paper
• Animal models of allergic and inflammatory conjunctivitis

  2003cited by this paper
• Heterologous immunity: an overlooked barrier to tolerance

  2003cited by this paper
• A Chimeric Mouse Model of Gaucher Disease

  2002cited by this paper
• Preclinical safety evaluation of biotechnology-derived pharmaceuticals

  2002cited by this paper
• Practical aspects of experimental design in animal research.

  2002cited by this paper
• Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.

  2002cited by this paper
• Passive transfer of Lambert‐Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission

  2002cited by this paper
• Retinal degeneration mutants in the mouse.

  2002cited by this paper
• Animal models in research on retinal degenerations: past progress and future hope.

  2002cited by this paper
• Alterations in retinal rod outer segment fatty acids and light-damage susceptibility in P23H rats.

  2002cited by this paper
• Human hereditary hepatic porphyrias.

  2002cited by this paper
• Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report

  2002cited by this paper
• Immune response to enzyme replacement therapy: single epitope control of antigen distribution from circulation.

  2002cited by this paper
• Animal model of axonal Guillain‐Barré syndrome induced by sensitization with GM1 ganglioside

  2001cited by this paper
• Recent progress in lysosomal α-mannosidase and its deficiency

  2001cited by this paper

• Food-derived bioactive compounds targeting mitophagy: emerging nutritional strategies against sarcopenia

  2025cites this paper
• Widefield OCT Angiography.

  2025cites this paper
• Implementation status of pharmacological studies in the development of orphan drugs

  2024cites this paper
• Isolation and Proteomic Analysis of Mouse Serum Small Extracellular Vesicles for Individual Subject Analysis.

  2022cites this paper
• Genetically modified mice for research on human diseases: A triumph for Biotechnology or a work in progress?

  2022cites this paper
• Genes Regulating Spermatogenesis and Sperm Function Associated With Rare Disorders

  2021cites this paper
• Regulatory Standards in Orphan Medicinal Product Designation in the EU

  2021cites this paper
• Tailored Biosensors for Drug Screening, Efficacy Assessment, and Toxicity Evaluation.

  2021cites this paper
• Orphan Drugs

  2021cites this paper
• The rapidly evolving view of lysosomal storage diseases

  2021cites this paper
• Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases

  2020cites this paper
• A putative silencer variant in a spontaneous canine model of retinitis pigmentosa

  2020cites this paper
• The Value of Mouse Models of Rare Diseases: A Spanish Experience

  2020cites this paper
• The translational value of animal models in orphan medicines designations for rare paediatric neurological diseases.

  2020cites this paper
• Current progress with mammalian models of mitochondrial DNA disease

  2020cites this paper
• Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions.

  2018cites this paper
• Maternal Inheritance of a Recessive RBP4 Defect in Canine Congenital Eye Disease

  2018cites this paper
• Behavioral Phenotyping Assays for Genetic Mouse Models of Neurodevelopmental, Neurodegenerative, and Psychiatric Disorders.

  2017cites this paper
• Catheterization of the gallbladder: A novel mouse model of severe acute cholangitis

  2017cites this paper
• Appendix A – Legal Framework on the Scientific Use of Animals in Research

  2017cites this paper
• The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact

  2017cites this paper
• Drug discovery and development for rare genetic disorders

  2017cites this paper
• Ocular delivery systems for the administration of antibody therapeutics

  2017influential citation
• Clinical Effects of Hydrogen Administration: From Animal and Human Diseases to Exercise Medicine

  2016cites this paper
• Spontaneously occurring fundus findings observed using confocal scanning laser ophthalmoscopy in wild type Sprague Dawley rats.

  2016cites this paper
• Long Coronary Lesions: Challenging Cases for Percutaneous Coronary Intervention

  2016cites this paper
• Heat shock protein–based therapy as a potential candidate for treating the sphingolipidoses

  2016cites this paper
• Disease models for the development of therapies for lysosomal storage diseases

  2016cites this paper
• Integrative Systems Biology Investigation of Fabry Disease

  2016cites this paper
• Animal Models with a Genetic Alteration of the ACE2/Ang-(1-7)/Mas Axis

  2015influential citation
• Model Organisms in the Fight against Muscular Dystrophy: Lessons from Drosophila and Zebrafish

  2015cites this paper
• The use of animal models in disease research

  2015cites this paper
• INTERNATIONAL RARE DISEASE RESEARCH CONSORTIUM

  2015cites this paper
• Establishing medical plausibility in the context of orphan medicines designation in the European Union

  2014cites this paper
• Glucocerebrosidase inhibitors: future drugs for the treatment of Gaucher disease?

  2014cites this paper
• Advances in the treatment of neuronal ceroid lipofuscinosis

  2013cites this paper
• Drosophila as a starting point for developing therapeutics for the rare disease Duchenne Muscular Dystrophy

  2013cites this paper
• Advances in the treatment of neuronal ceroid lipofuscinosis

  2013cites this paper